We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WINT
101
DELISTED
Windtree Therapeutics Inc
WINT
$1.35M 0.09%
+42,857
New +$1.34M
STML
102
DELISTED
Stemline Therapeutics, Inc.
STML
$1.33M 0.09%
+68,100
New +$1.82M
OREX
103
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.27M 0.08%
226
-383
-63% -$21.5K
CASC
104
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.26M 0.08%
119,667
+9,734
+9% +$109K
BMY icon
105
PUT
Bristol-Myers Squibb
BMY
$130B
$1.23M 0.08%
232
+172
+287% +$8.76K
NBIX icon
106
CALL
Neurocrine Biosciences
NBIX
$18.4B
$1.22M 0.08%
+1,307
New +$12.8K
BCRX icon
107
CALL
BioCryst Pharmaceuticals
BCRX
$2.48B
$1.2M 0.08%
1,576
+963
+157% +$6.1K
EXAS
108
CALL
DELISTED
Exact Sciences
EXAS
$1.2M 0.08%
1,025
– –
TCRT icon
109
CALL
Alaunos Therapeutics
TCRT
$4.64M
$1.12M 0.07%
17
+1
+6% +$595
TCRT icon
110
PUT
Alaunos Therapeutics
TCRT
$4.64M
$1.11M 0.07%
17
+5
+42% +$2.98K
CHTP
111
PUT
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$1.11M 0.07%
+2,509
New +$8.48K
LITS
112
Lite Strategy Inc
LITS
$33M
$1.1M 0.07%
+6,900
New +$1.18M
AVNR
113
PUT
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.1M 0.07%
3,264
+730
+29% +$3.02K
STAA icon
114
CALL
STAAR Surgical
STAA
$1.13B
$1.09M 0.07%
+676
New +$9.04K
HALO icon
115
CALL
Halozyme
HALO
$9.9B
$1.05M 0.07%
+700
New +$9K
MBOT icon
116
Microbot Medical
MBOT
$113M
$1.04M 0.07%
+523
New +$1.11M
DYAX
117
DELISTED
DYAX CORPORATION
DYAX
$1.03M 0.07%
136,581
+37,123
+37% +$282K
NVAX icon
118
PUT
Novavax
NVAX
$1.21B
$984K 0.06%
+96
New +$6.78K
CVM icon
119
CEL-SCI Corp
CVM
$21M
$983K 0.06%
+2,217
New +$1.36M
DVAX
120
DELISTED
Dynavax Technologies
DVAX
$980K 0.06%
+50,000
New +$732K
ECYT
121
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$973K 0.06%
910
+500
+122% +$5.52K
ARWR icon
122
PUT
Arrowhead Research
ARWR
$12.1B
$971K 0.06%
+895
New +$7.16K
INFI
123
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$967K 0.06%
+70,000
New +$989K
ALXA
124
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$965K 0.06%
2,040
– –
INCY icon
125
PUT
Incyte
INCY
$26B
$947K 0.06%
+187
New +$8.14K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.